BattelleCRO, Inc. and Global Clinical Trials, Llc Sign Joint Marketing agreement to Provide Support and Service For Pharmaceutical, Biotechnology and Medical Device Clients

December 5, 2006--BattelleCRO, Inc. (BattelleCRO) a leading full-service Contract Research Organization with more than 10 years experience, announced today that it has signed a non-exclusive joint marketing agreement with Global Clinical Trials, LLC (GCT). GCT is a full-service Contract Research Organization, which provides Phase II-IV services for clinical trials conducted in Russia, former Soviet Republics, and Eastern Europe.

 

This collaboration allows for the seamless integration of both companies' resources in responding to the global clinical trial demands of pharmaceutical, biotechnology, and medical device clients. By being able to jointly market each other's capabilities within their respective countries, clients can gain the advantage of working with a multinational organization without having to absorb the additional overhead of paying for infrastructure when it is not being fully utilized.

 

"This agreement with GCT is part of our overall international partner strategy. Extending our global reach into Russia, former Soviet Republics, and Eastern Europe provides us not only with access to a large treatment-naïve population but allows us to take full advantage of underutilized local medical, clinical, and regulatory expertise," remarked Howard Golub, PhD, MD, President of BattelleCRO, Inc.

 

"Working closely with our international partners like GCT provides a number of distinct advantages for our clients, specifically: access to patients as well as expert resources that understand the regulatory environment, the language, and the local customs. Partnering allows us to place studies into the countries where it is most appropriate and not where we happen to have excess capacity," added Peter C. Powers, Vice President, Business Development of BattelleCRO, Inc.

 

"We are excited about this agreement, which allows both organizations the opportunity to engage in larger multi-national trials. This cooperation also provides us the opportunity to offer our worldwide clients access to the US market through a recognized leader in research and development," stated Eugene Selivra, MD, Chief Executive Officer of GCT.

 

About BattelleCRO

 

BattelleCRO is a wholly owned subsidiary of Battelle that supports Phase I-IV clinical development programs for pharmaceutical, biotechnology, medical device, nutraceutical, government clients, and bio-defense efforts (including chemical and biomedical countermeasures). As a full service one-stop provider, BattelleCRO supports the client's overall market strategy from toxicology, through IND submissions, clinical trials, FDA approval, and post-marketing monitoring. For more information, visit www.BattelleCRO.com or contact Peter C. Powers at (617) 618-5103 e-mail: ppowers@battellecro.com.

 

About Global Clinical Trials, LLC

 

Global Clinical Trials is a full service CRO providing clinical research services across the breadth of the Russian Federation, former Soviet Republics, and Eastern Europe. Headquartered in Princeton NJ, with offices in St. Petersburg and Moscow, Russia (RCT), Sofia, Bulgaria (BCT) and Kiev, Ukraine (UCT) they have been conducting clinical research for the pharmaceutical and biotech industry since 2001.

Having expanded their experience across numerous therapeutic areas working with international clients from across the globe, GCT provides an experienced regional presence with international perspective. GCT provides the kind of professionalism and attention to detail you would expect from your own team, except with the regional knowledge and local experience that can only come from years of working within the Region. For more information, visit www.cro-rct.com or contact Rick Leach at (609) 731-2225 e-mail: rl@cro-rct.ru.

 

About Battelle

 

Battelle is a global leader in science and technology. Headquartered in Columbus, Ohio, it develops and commercializes technology and manages laboratories for customers. Battelle, with the national labs that it manages or co-manages, oversees 20,000 staff members and conducts $3.7 billion in annual research and development. Battelle provides complete safety pharmacology, cardiovascular and respiratory physiology, pulmonary delivery, and other non-clinical safety assessment services to pharmaceutical and biotechnology clients. Battelle also provides analytical chemistry capabilities for pre-clinical and clinical drug development and expertise for analyzing and interpreting PK/TK data for such purposes as chemical safety evaluations, risk assessments, and/or IND applications. For more information, visit www.battelle.org or contact Michael Brooker at (614) 424-6372 e-mail: brookerm@battelle.org.